Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review
Language: 
English
Short Title: 
Genome Editing of Monogenic Neuromuscular Diseases
Abstract: 

Importance: Muscle weakness, the most common symptom of neuromuscular disease, may result from muscle dysfunction or may be caused indirectly by neuronal and neuromuscular junction abnormalities. To date, more than 780 monogenic neuromuscular diseases, linked to 417 different genes, have been identified in humans. Genome-editing methods, especially the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) system, hold clinical potential for curing many monogenic disorders, including neuromuscular diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1. Objectives: To provide an overview of genome-editing approaches; to summarize published reports on the feasibility, efficacy, and safety of current genome-editing methods as they relate to the potential correction of monogenic neuromuscular diseases; and to highlight scientific and clinical opportunities and obstacles toward permanent correction of disease-causing mutations responsible for monogenic neuromuscular diseases by genome editing. Evidence Review: PubMed and Google Scholar were searched for articles published from June 30, 1989, through June 9, 2016, using the following keywords: genome editing, CRISPR-Cas9, neuromuscular disease, Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1. The following sources were reviewed: 341 articles describing different approaches to edit mammalian genomes; 330 articles describing CRISPR-Cas9-mediated genome editing in cell culture lines (in vitro) and animal models (in vivo); 16 websites used to generate single-guide RNA; 4 websites for off-target effects; and 382 articles describing viral and nonviral delivery systems. Articles describing neuromuscular diseases, including Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1, were also reviewed. Findings: Multiple proof-of-concept studies reveal the feasibility and efficacy of genome-editing-meditated correction of monogenic neuromuscular diseases in cultured cells and animal models. Conclusions and Relevance: Genome editing is a rapidly evolving technology with enormous translational potential once efficacy, delivery, and safety issues are addressed. The clinical impact of this technology is that genome editing can permanently correct disease-causing mutations and circumvent the hurdles of traditional gene- and cell-based therapies.

Author(s): 
Long, Chengzu
Amoasii, Leonela
Bassel-Duby, Rhonda
Olson, Eric N.
Item Type: 
Journal Article
Publication Title: 
JAMA neurology
Journal Abbreviation: 
JAMA Neurol
Publication Date: 
11/1/2016
Publication Year: 
2016
Pages: 
1349-1355
Volume: 
73
Issue: 
11
ISSN: 
2168-6157
DOI: 
10.1001/jamaneurol.2016.3388
Library Catalog: 
PubMed
Extra: 
PMID: 27668807

Turabian/Chicago Citation

Chengzu Long, Leonela Amoasii, Rhonda Bassel-Duby and Eric N. Olson. 11/1/2016. "Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review." JAMA neurology 73: 11: 1349-1355. 10.1001/jamaneurol.2016.3388.

Wikipedia Citation

<ref> {{Cite journal | doi = 10.1001/jamaneurol.2016.3388 | issn = 2168-6157 | volume = 73 | pages = 1349-1355 | last = Long | first = Chengzu | coauthors = Amoasii, Leonela, Bassel-Duby, Rhonda, Olson, Eric N. | title = Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review | journal = JAMA neurology | date = 11/1/2016 | pmid = | pmc = }} </ref>